Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck
Jennifer L. Leddon(University of Cincinnati), Trisha M. Wise‐Draper(University of Cincinnati), Maria Mathews(University of Cincinnati), Sulsal Haque(Palmetto Hematology Oncology), Benjamin H. Hinrichs(University of Cincinnati), Yash Patil(University of Cincinnati), W. Michael Korn(Itasca Community College), Vinita Takiar(University of Cincinnati), Shuchi Gulati(Comprehensive Blood & Cancer Center), Misako Nagasaka(University of California, Irvine), Nusrat Harun(Cytel (United States)), Sarah Palackdharry(University of Cincinnati), Roman Jandarov(University of Cincinnati), Nicky Kurtzweil(University of Cincinnati), Julie McGrath(Caris Life Sciences (United States)), Brian Cervenka(University of Cincinnati), Alice L. Tang(University of Cincinnati), Casey Allen(University of Cincinnati), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute), Muhammed Kashif Riaz(University of Cincinnati), Chad Zender(University of Cincinnati)
Cited by 26
Related Papers
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653
Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
|Cancer Research|2009|390
Mre11 Nuclease Activity Has Essential Roles in DNA Repair and Genomic Stability Distinct from ATM Activation
|Cell|2008|341